Cargando…

The Safety of COVID-19 Vaccinations—We Should Rethink the Policy

Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Method: We calculated the number needed to vaccinate (NNTV) from a large Israeli field study to prevent one death. We accessed the Adverse Drug Reactions (ADR) database o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walach, Harald, Klement, Rainer J., Aukema, Wouter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294615/ https://www.ncbi.nlm.nih.gov/pubmed/34202529 http://dx.doi.org/10.3390/vaccines9070693

Ejemplares similares

The risk‐benefit ratio of Covid‐19 vaccines: Publication policy by retraction does nothing to improve it
por: Walach, Harald, et al.
Publicado: (2022)

Retraction: Walach et al. The Safety of COVID-19 Vaccinations—We Should Rethink the Policy. Vaccines 2021, 9, 693
Publicado: (2021)

SEIR models in the light of Critical Realism – A critique of exaggerated claims about the effectiveness of Covid 19 vaccinations
por: Klement, Rainer J., et al.
Publicado: (2023)

Expression of Concern: Walach et al. The Safety of COVID-19 Vaccinations—We Should Rethink the Policy. Vaccines 2021, 9, 693
por: Office, Vaccines Editorial
Publicado: (2021)

Is the Network of World Economic Forum Young Global Leaders Associated With COVID-19 Non-Pharmaceutical Intervention Severity?
por: Klement, Rainer J, et al.
Publicado: (2022)

Identifying factors associated with COVID-19 related deaths during the first wave of the pandemic in Europe
por: Klement, Rainer Johannes, et al.
Publicado: (2022)

Why do people consent to receiving SARS-CoV-2 vaccinations? A representative survey in Germany
por: Walach, Harald, et al.
Publicado: (2022)

Safety of COVID-19 vaccines administered in the EU: Should we be concerned?
por: Hernández, Antonio F., et al.
Publicado: (2021)

Emerging Zoonotic Diseases: Should We Rethink the Animal–Human Interface?
por: Magouras, Ioannis, et al.
Publicado: (2020)

Rethinking the Current Older-people-first Policy for COVID-19 Vaccination in Japan
por: Matsui, Kenji, et al.
Publicado: (2021)

Rethinking Urban and Food Policies to Improve Citizens Safety After COVID-19 Pandemic
por: Galimberti, Andrea, et al.
Publicado: (2020)

Rethinking Lockdown Policies in the Pre-Vaccine Era of COVID-19: A Configurational Perspective
por: Zhang, Ziang, et al.
Publicado: (2022)

Application of Bayesian evidence synthesis to modelling the effect of ketogenic therapy on survival of high grade glioma patients
por: Klement, Rainer J., et al.
Publicado: (2018)

Rethinking clinical study data: why we should respect analysis results as data
por: Barros, Joana M., et al.
Publicado: (2022)

Should we vaccinate the better seroconverters or the most vulnerable? Game changing insights for COVID-19 vaccine prioritization policies
por: AbdelMassih, Antoine, et al.
Publicado: (2021)

COVID-19 Vaccination. Where Are We and Where Should We Go?
por: Peña-Otero, David
Publicado: (2022)

Maximum incubation period for COVID-19 infection: Do we need to rethink the 14-day quarantine policy?
por: Bikbov, Boris, et al.
Publicado: (2021)

Management Strategy in Non-Limb-Threatening Acute Ischaemia of Limbs: Should We Rethink?
por: Hussain, Syed M. Asim, et al.
Publicado: (2016)

Should physicians rethink travel to conferences?
por: Will, Erin C.
Publicado: (2022)

COVID-19 vaccine: what are we doing and what should we do?
por: Candelli, Marcello
Publicado: (2022)

Vaccine safety concerns: Should we be changing the way we support immunization?
por: MacDonald, Noni E, et al.
Publicado: (2020)

Rethinking social policy : race, poverty, and the underclass /
por: Jencks, Christopher
Publicado: (1993)

Should medical educators rethink on-the-spot quizzing?
por: Duong, Diana
Publicado: (2021)

Should we allocate more COVID-19 vaccine doses to non-vaccinated individuals?
por: Ben Chaouch, Zied, et al.
Publicado: (2022)

Rethinking Human Embryo Research Policies
por: Matthews, Kirstin R. W., et al.
Publicado: (2021)

Why we should not ‘just use age’ for COVID-19 vaccine prioritisation
por: Smith, Maxwell J
Publicado: (2022)

How Should we Handle Safety?
por: Albert, M, et al.
Publicado: (2001)

Whither are we bound? Rethinking the gendered frailty during COVID-19 pandemic
por: Gyasi, Razak M., et al.
Publicado: (2020)

Rethinking patient safety
por: Woodward, Suzette
Publicado: (2017)

Patients and agents – or why we need a different narrative: a philosophical analysis
por: Walach, Harald, et al.
Publicado: (2018)

Vox populi and public policy: why should we care?
por: Miller, Henry I
Publicado: (2003)

Bayes Lines Tool (BLT): a SQL-script for analyzing diagnostic test results with an application to SARS-CoV-2-testing
por: Aukema, Wouter, et al.
Publicado: (2022)

Safety of COVID-19 vaccines: who should see an allergist
Publicado: (2021)

COVID-19: rethinking risk
por: Schwalbe, Nina, et al.
Publicado: (2020)

Should we stop methotrexate or not for vaccination?
por: Durez, Patrick, et al.
Publicado: (2023)

Systemic immunosuppression in times of COVID‐19: Do we need to rethink our standards?
por: Grabbe, Stephan, et al.
Publicado: (2020)

Rethinking the politics and implementation of health in all policies
por: Wismar, Matthias, et al.
Publicado: (2013)

Total rethink: why entrepreneurs should act like revolutionaries
por: McCourt, David
Publicado: (2019)

Wuhan Covid19 data – more questions than answers
por: Walach, Harald, et al.
Publicado: (2020)

Covid-19 symptoms rethink
por: Hamzelou, Jessica
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f8nus756gtghneanf8adfa8j9u